Announcements Trials
Browse Landscape

Phase

Phase NA 1Phase 2/3 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1

Conditions

Squamous Cell Carcinoma of Head and Neck 3Carcinoma 3Prostatic Neoplasms 2Oropharyngeal Neoplasms 2Nasopharyngeal Carcinoma 2Head and Neck Neoplasms 2Uterine Cervical Neoplasms 1Neoplasms, Squamous Cell 1Neoplasms 1Mouth Neoplasms 1Lung Neoplasms 1Laryngeal Neoplasms 1Hypopharyngeal Neoplasms 1Gallbladder Neoplasms 1Extensive Stage Small Cell Lung Carcinoma 1Epstein-Barr Virus Infections 1Carcinoma, Squamous Cell 1Advanced Glioblastoma 1

Interventions

dehydroftorafur 1Watchful Waiting 1Taxes 1Radiotherapy, Intensity-Modulated 1Platinum 1Paclitaxel 1Gemcitabine 1Fluorouracil 1Cisplatin 11,2-diaminocyclohexaneplatinum II citrate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2/3 × Epstein-Barr Virus Infections × Radiotherapy, Intensity-Modulated × Clear all
NCT02135042 2026-05-07

Individualized Treatment Treating Patients With Stage II-IVB Nasopharyngeal Cancer Based on EBV DNA

NRG Oncology

Phase 2/3 Active not recruiting
685 enrolled
Head & Neck

Nasopharyngeal Carcinoma, Epstein-Barr Virus Infections

Data powered by HemOnc (CC BY 4.0) Colophon âš¡